Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C9SY
|
|||
| Former ID |
DAP000414
|
|||
| Drug Name |
Vardenafil
|
|||
| Synonyms |
VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Approved | [1], [2] | |
| Therapeutic Class |
Antiimpotence Agents
|
|||
| Company |
Bayer Pharmaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H32N6O4S
|
|||
| Canonical SMILES |
CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C
|
|||
| InChI |
1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
|
|||
| InChIKey |
SECKRCOLJRRGGV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 224785-90-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
585747, 833312, 7891048, 7980307, 10235224, 14785997, 14932815, 28477354, 44439098, 46506777, 46515101, 48034817, 49737956, 50012454, 50112786, 50365874, 53787736, 60818951, 85789651, 89521986, 92308880, 93342988, 96025351, 99645193, 103558698, 103854631, 104253666, 104386549, 117886401, 124757847, 125164651, 125433166, 126680944, 129223014, 131856665, 134337710, 134358350, 135067955, 135610269, 135692501, 136352775, 136946635, 137002811, 137053214, 142001694, 152134184, 160650107, 160849672, 160964203, 162037977
|
|||
| ChEBI ID |
CHEBI:46295
|
|||
| ADReCS Drug ID | BADD_D02335 ; BADD_D02336 | |||
| SuperDrug ATC ID |
G04BE09
|
|||
| SuperDrug CAS ID |
cas=224785904
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Vardenafil (adjusted p-values: 1.06E-03). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Vardenafil (adjusted p-values: 6.63E-03). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Vardenafil (adjusted p-values: 5.87E-04). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Vardenafil (adjusted p-values: 3.91E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Binder | [4] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7320). | |||
| REF 2 | Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.